CVRx, Inc. CVRX
1.38 USD +0.01 (+0.85%)
Nov 3, 2026, 3:45 PM EST
1.34 Day range 1.45
1.26 52-week range 10.63
- YTD
- -80.54%
- 1 year
- -86.66%
- Market cap
- 36.90M
- Revenue (ttm)
- 47.26M
- Profit margin
- -123.75%
- EPS (ttm)
- -1.97
- Shares out
- 24.26M
- Forward P/E
- -5.84
- YTD return
- -80.54%
- 1-year return
- -86.66%
- Volume
- 194.53K
- Avg volume
- 966.55K
- Open
- 1.38
- Previous close
- 1.37
- Day's range
- 1.34 – 1.45
- 52-week range
- 1.26 – 10.63
- Beta
- 1.11
- Analysts
- Buy
- Price target
- 18.17 (+1214.9%)
- Earnings date
- Jan 23, 2025
1Y -8.62 (-86.29%)
Key statistics
- Enterprise value
- 244.11M
- PEG ratio
- 0.00
- Price / sales
- 6.42
- Price / book
- 4.64
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Revenue growth
- 27.20%
- Free cash flow
- -21.40M
- Total cash
- 100.16M
- Total debt
- 50.44M
- Return on equity
- -79.02%
- Short % of float
- 12.35%
- 50-day average
- 12.92
- 200-day average
- 11.61
Analyst view
Consensus: buy
Buy
Price target (mean) 18.17 +1214.9% upside
Now 1.38
- Target (low)
- 13.00
- Target (mean)
- 18.17
- Target (high)
- 22.00
Ratings (0m) 7 5 buy · 2 hold · 0 sell
- Strong buy1
- Buy4
- Hold2
- Sell0
- Strong sell0
Next earnings
Jan 23, 2025
Expected Jan 23, 2025. Consensus EPS estimate -0.38393.
Financials — quick view
CVRX Revenue — quarterly 15.71M
CVRX Net income — quarterly -14.04M
CVRX EPS — quarterly -0.53
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Jan 23, 2025 | Dec 1, 2024 | -0.38 | — | — | — |
| Oct 29, 2024 | Sep 1, 2024 | -0.45 | -0.57 | -0.12 | -26.67% |
| Jul 29, 2024 | Jun 1, 2024 | -0.51 | — | — | — |
| Jul 29, 2024 | Jun 1, 2024 | -0.51 | -0.65 | -0.14 | -27.45% |
| Apr 30, 2024 | Mar 1, 2024 | -0.53 | — | — | — |
| Apr 30, 2024 | Mar 1, 2024 | -0.53 | -1.04 | -0.51 | -96.23% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Dec 9, 2024 | Canaccord Genuity | main | Buy | Buy |
| Nov 4, 2024 | Craig-Hallum | main | Buy | Buy |
| Oct 30, 2024 | Lake Street | main | Buy | Buy |
| Oct 30, 2024 | Canaccord Genuity | main | Buy | Buy |
| Oct 30, 2024 | Piper Sandler | reit | Overweight | Overweight |
| Oct 23, 2024 | Cantor Fitzgerald | reit | Overweight | Overweight |
About CVRx, Inc.
CVRx, Inc., a commercial-stage medical device company, focuses on developing, manufacturing, and commercializing neuromodulation solutions for patients with cardiovascular diseases. The company offers Barostim, a neuromodulation device indicated to improve symptoms for patients with heart failure with reduced ejection fraction or systolic heart failure. It sells its products through direct sales force, as well as sales agents and independent distributors in the United States, Germany, and internationally. The company was incorporated in 2000 and is headquartered in Minneapolis, Minnesota.
- Sector
- Healthcare
- Industry
- Medical Devices
- Country
- United States
- Website
- cvrx.com
News
CVRx to Participate in Upcoming Investor Conferences 
CVRx to Report Third Quarter 2026 Financial and Operating Results and Host Conference Call on November 5, 2026 
CVRx Reports Q2 2026 Results: Full Earnings Call Transcript 
HAGENS BERMAN, NATIONAL SECURITIES LAW FIRM, Encourages CVRx Inc. (CVRX) Investors with Substantial Losses to Contact Firm: Investigating Potential Securities Fraud Following 59% Stock Drop 
12 Health Care Stocks Moving In Wednesday's Intraday Session 
CVRx To Present Barostim Data And Clinical Research At HFSA Annual Scientific Meeting 2026 
CVRx Announces Late-Breaking Data and New Clinical Evidence on Barostim at the HFSA Annual Scientific Meeting 2026 
HAGENS BERMAN, NATIONAL SECURITIES LAW FIRM, Encourages CVRx Inc. (CVRX) Investors with Substantial Losses to Contact Firm: Investigating Potential Securities Fraud Following 59% Stock Drop 
CVRx Appoints John Landry CFO, Effective Oct. 12, Succeeding Jared Oasheim 
CVRx Appoints John Landry as Chief Financial Officer
Your note
Sign in to keep a note on CVRX — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| BEHBAHANI ALI | Director | Conversion of Exercise of derivative security | Dec 13, 2023 | 316 |
| GALLE LIZ | Officer | Conversion of Exercise of derivative security | Oct 15, 2023 | 778 |
| HYKES KEVIN | Chief Executive Officer | Purchase | Aug 4, 2024 | 30,000 |
| JOHNSON & JOHNSON INNOVATION - JJDC, INC. | Beneficial Owner of more than 10% of a Class of Security | Conversion of Exercise of derivative security | Feb 28, 2024 | 0 |
| OASHEIM JARED | Chief Financial Officer | Conversion of Exercise of derivative security | Sep 17, 2023 | 15,447 |
| PALMER CRAIG E | Officer | Conversion of Exercise of derivative security | Mar 24, 2024 | 1,229 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Johnson & Johnson | 16.91% | 4,103,430 | 51.29M | Sep 29, 2024 |
| NEA Management Company, LLC | 9.77% | 2,370,542 | 29.63M | Sep 29, 2024 |
| Blackrock Inc. | 3.75% | 909,423 | 11.37M | Sep 29, 2024 |
| Vanguard Group Inc | 3.40% | 824,290 | 10.30M | Sep 29, 2024 |
| Parkman Healthcare Partners LLC | 2.81% | 682,897 | 8.54M | Sep 29, 2024 |
| Schonfeld Strategic Advisors Llc | 2.25% | 545,300 | 6.82M | Sep 29, 2024 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Vanguard Total Stock Market Index Fund | 2.24% | 544,348 | 6.80M | Sep 29, 2024 |
| iShares Russell 2000 ETF | 1.40% | 338,536 | 4.23M | Oct 30, 2024 |
| College Retirement Equities Fund-Stock Account | 0.69% | 167,840 | 2.10M | Sep 29, 2024 |
| Vanguard Extended Market Index Fund | 0.68% | 165,802 | 2.07M | Sep 29, 2024 |
| Trust for Professional Managers-Mairs & Power Small Cap Fund | 0.59% | 142,456 | 1.78M | Sep 29, 2024 |
| Fidelity Small Cap Index Fund | 0.56% | 136,885 | 1.71M | Aug 30, 2024 |